TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2.

The prognosis for patients with chemo-refractory rhabdomyosarcoma remains poor. The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a hopeful candidate for new strategies in chemotherapy. The effects of TRAIL and melphalan (Mel) in the rhabdomyosarcoma cell line TE-671 were investigated by colorimetric caspase assays and flow cytometry. TRAIL induced the activation of caspases-2, -3 and -8, but not the activation of caspase-9, in the Mel-resistant TE-671 cells. Inhibition of caspase-2 with the caspase-2 inhibitor z-VDVAD-fmk significantly down-regulated the TRAIL-induced caspase-3 activation, as well as the TRAIL-induced cytotoxicity. When TE-671 cells were treated with a combination of Mel and TRAIL, a significant synergism of drug-induced cytotoxicity was obtained. The inhibition of caspase-2 could completely abolish caspase-3 activation, suggesting that TRAIL sensitises TE-671 cells for Mel-induced cytotoxicity via a caspase-2- and -3-dependent mechanism. In conclusion, it was shown, for the first time, that TRAIL could sensitise Mel-resistant tumour cells to melphalan.

[1]  I. H. Engels,et al.  Caspase-2 Can Function Upstream of Bid Cleavage in the TRAIL Apoptosis Pathway* , 2004, Journal of Biological Chemistry.

[2]  C. Kusumoto,et al.  Endogenously generated hydrogen peroxide is required for execution of melphalan-induced apoptosis as well as oxidation and externalization of phosphatidylserine. , 2004, Chemical research in toxicology.

[3]  D. Körholz,et al.  Drug-induced caspase-3 activation in a Ewing tumor cell line and primary Ewing tumor cells. , 2004, Anticancer research.

[4]  B. Dörken,et al.  Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. , 2004, Oncogene.

[5]  C. Beam,et al.  Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. , 2003, Cancer research.

[6]  Helen Conroy,et al.  Caspase‐activation pathways in apoptosis and immunity , 2003, Immunological reviews.

[7]  Seamus J. Martin,et al.  Cell Stress-Associated Caspase Activation: Intrinsically Complex? , 2003, Science's STKE.

[8]  D. Green,et al.  A unified model for apical caspase activation. , 2003, Molecular cell.

[9]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[10]  CM Troy,et al.  Caspase-2 redux , 2003, Cell Death and Differentiation.

[11]  D. Vaux,et al.  Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9 , 2002, Cell Death and Differentiation.

[12]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[13]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[14]  J. Houghton,et al.  Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  G. Salvesen,et al.  Caspases - controlling intracellular signals by protease zymogen activation. , 2000, Biochimica et biophysica acta.

[16]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[17]  L. Helman,et al.  Rhabdomyosarcoma: an overview. , 1999, The oncologist.

[18]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[19]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[20]  Emad S. Alnemri,et al.  Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.

[21]  M. Lutter,et al.  Biochemical pathways of caspase activation during apoptosis. , 1999, Annual review of cell and developmental biology.

[22]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[23]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[24]  A. Pappo,et al.  Rhabdomyosarcoma: biology and therapy. , 1997, Cancer treatment and research.

[25]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[26]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[27]  T. R. CHEN,et al.  Cell identity resolved , 1989, Nature.

[28]  M. Stratton,et al.  Misidentified cell , 1989, Nature.

[29]  J. Graham-Pole,et al.  Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Gardner,et al.  Establishment of a human medulloblastoma cell line , 1977, International journal of cancer.